vs
Hamilton Insurance Group, Ltd.（HG）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Hamilton Insurance Group, Ltd.的1.1倍（$772.1M vs $728.3M），Hamilton Insurance Group, Ltd.净利率更高（29.5% vs 12.7%，领先16.7%），Hamilton Insurance Group, Ltd.同比增速更快（27.7% vs 5.9%），过去两年Revvity的营收复合增速更高（9.0% vs 5.2%）
汉密尔顿保险集团有限公司是一家多元化的保险及相关金融服务控股公司，总部位于百慕大汉密尔顿。公司于1999年10月25日从美国特拉华州迁册至此，主要通过旗下保险子公司及其他关联机构开展核心业务，业务布局覆盖多元保险服务场景。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HG vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$728.3M
营收增速更快
HG
高出21.8%
5.9%
净利率更高
HG
高出16.7%
12.7%
两年增速更快
RVTY
近两年复合增速
5.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $728.3M | $772.1M |
| 净利润 | $214.6M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 26.0% | 14.5% |
| 净利率 | 29.5% | 12.7% |
| 营收同比 | 27.7% | 5.9% |
| 净利润同比 | 188.3% | 3.9% |
| 每股收益（稀释后） | $1.67 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HGRVTY
| Q4 25 | $728.3M | $772.1M | ||
| Q3 25 | $667.6M | $698.9M | ||
| Q2 25 | $740.8M | $720.3M | ||
| Q1 25 | $768.8M | $664.8M | ||
| Q4 24 | $570.5M | $729.4M | ||
| Q3 24 | $512.8M | $684.0M | ||
| Q2 24 | $587.9M | $691.7M | ||
| Q1 24 | $658.6M | $649.9M |
净利润HGRVTY
| Q4 25 | $214.6M | $98.4M | ||
| Q3 25 | $176.4M | $46.7M | ||
| Q2 25 | $267.8M | $53.9M | ||
| Q1 25 | $181.3M | $42.2M | ||
| Q4 24 | $74.4M | $94.6M | ||
| Q3 24 | $61.0M | $94.4M | ||
| Q2 24 | $200.4M | $55.4M | ||
| Q1 24 | $277.3M | $26.0M |
毛利率HGRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率HGRVTY
| Q4 25 | 26.0% | 14.5% | ||
| Q3 25 | 27.0% | 11.7% | ||
| Q2 25 | 36.5% | 12.6% | ||
| Q1 25 | 24.0% | 10.9% | ||
| Q4 24 | 13.4% | 16.3% | ||
| Q3 24 | 12.5% | 14.3% | ||
| Q2 24 | 34.5% | 12.4% | ||
| Q1 24 | 42.2% | 6.8% |
净利率HGRVTY
| Q4 25 | 29.5% | 12.7% | ||
| Q3 25 | 26.4% | 6.7% | ||
| Q2 25 | 36.1% | 7.5% | ||
| Q1 25 | 23.6% | 6.4% | ||
| Q4 24 | 13.0% | 13.0% | ||
| Q3 24 | 11.9% | 13.8% | ||
| Q2 24 | 34.1% | 8.0% | ||
| Q1 24 | 42.1% | 4.0% |
每股收益（稀释后）HGRVTY
| Q4 25 | $1.67 | $0.86 | ||
| Q3 25 | $1.32 | $0.40 | ||
| Q2 25 | $1.79 | $0.46 | ||
| Q1 25 | $0.77 | $0.35 | ||
| Q4 24 | $0.35 | $0.77 | ||
| Q3 24 | $0.74 | $0.77 | ||
| Q2 24 | $1.20 | $0.45 | ||
| Q1 24 | $1.38 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $919.9M |
| 总债务越低越好 | $149.7M | — |
| 股东权益账面价值 | $2.8B | $7.3B |
| 总资产 | $9.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.05× | — |
8季度趋势，按日历期对齐
现金及短期投资HGRVTY
| Q4 25 | $1.1B | $919.9M | ||
| Q3 25 | $955.1M | $931.4M | ||
| Q2 25 | $985.6M | $991.8M | ||
| Q1 25 | $838.5M | $1.1B | ||
| Q4 24 | $996.5M | $1.2B | ||
| Q3 24 | $957.4M | $1.2B | ||
| Q2 24 | $1.0B | $2.0B | ||
| Q1 24 | $1.1B | $1.7B |
总债务HGRVTY
| Q4 25 | $149.7M | — | ||
| Q3 25 | $149.7M | — | ||
| Q2 25 | $149.7M | — | ||
| Q1 25 | $150.0M | — | ||
| Q4 24 | $149.9M | — | ||
| Q3 24 | $149.9M | — | ||
| Q2 24 | $149.9M | — | ||
| Q1 24 | $149.9M | — |
股东权益HGRVTY
| Q4 25 | $2.8B | $7.3B | ||
| Q3 25 | $2.7B | $7.4B | ||
| Q2 25 | $2.6B | $7.6B | ||
| Q1 25 | $2.4B | $7.6B | ||
| Q4 24 | $2.3B | $7.7B | ||
| Q3 24 | $2.3B | $7.9B | ||
| Q2 24 | $2.2B | $7.9B | ||
| Q1 24 | $2.2B | $7.8B |
总资产HGRVTY
| Q4 25 | $9.6B | $12.2B | ||
| Q3 25 | $9.2B | $12.1B | ||
| Q2 25 | $8.9B | $12.4B | ||
| Q1 25 | $8.3B | $12.4B | ||
| Q4 24 | $7.8B | $12.4B | ||
| Q3 24 | $7.8B | $12.8B | ||
| Q2 24 | $7.6B | $13.4B | ||
| Q1 24 | $7.3B | $13.4B |
负债/权益比HGRVTY
| Q4 25 | 0.05× | — | ||
| Q3 25 | 0.06× | — | ||
| Q2 25 | 0.06× | — | ||
| Q1 25 | 0.06× | — | ||
| Q4 24 | 0.06× | — | ||
| Q3 24 | 0.06× | — | ||
| Q2 24 | 0.07× | — | ||
| Q1 24 | 0.07× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $293.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 1.37× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流HGRVTY
| Q4 25 | $293.4M | $182.0M | ||
| Q3 25 | $295.6M | $138.5M | ||
| Q2 25 | $218.4M | $134.3M | ||
| Q1 25 | $34.9M | $128.2M | ||
| Q4 24 | $284.1M | $174.2M | ||
| Q3 24 | $160.6M | $147.9M | ||
| Q2 24 | $156.4M | $158.6M | ||
| Q1 24 | $158.2M | $147.6M |
自由现金流HGRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率HGRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度HGRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率HGRVTY
| Q4 25 | 1.37× | 1.85× | ||
| Q3 25 | 1.68× | 2.97× | ||
| Q2 25 | 0.82× | 2.49× | ||
| Q1 25 | 0.19× | 3.03× | ||
| Q4 24 | 3.82× | 1.84× | ||
| Q3 24 | 2.63× | 1.57× | ||
| Q2 24 | 0.78× | 2.87× | ||
| Q1 24 | 0.57× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HG
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
